Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 1-10 of 747 for Mayo Clinic Cancer Center — Research

  • Results filtered:
  • Study phase: 2 (1/2, 2, 2/3)
Edit search filters
  1. Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma

    Rochester, MN

  2. SMAC Mimetic LCL161 Alone or With Cyclophosphamide in Treating Patients With Relapsed or Refractory Multiple Myeloma

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  3. Oral Rigosertib in Low Risk MDS Patients Refractory to ESAs

    Rochester, MN

  4. Birinapant With 5-azacitidine in MDS Subjects Who Are Naïve, Have Relapsed or Are Refractory to 5-azacitidine Therapy

    Scottsdale/Phoenix, AZ, Jacksonville, FL

  5. Erismodegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma

    Rochester, MN

  6. Phase II Study of EUS-guided Verteporfin PDT in Solid Pancreatic Tumors

    Rochester, MN

  7. A Study to Evaluate Daratumumab and Ibrutinib to Treat Relapsed / Refractory Chronic Lymphocytic Leukemia Treatment (DIRECT)

    Jacksonville, FL

  8. A Study to Evaluate the Safety and Immunological Effect of Pembrolizumab in Resectable or Borderline Resectable Pancreatic Cancer

    Scottsdale/Phoenix, AZ

  9. CC-220-MM-001: A Phase 1b/2a Multicenter, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CC-220 as Monotherapy and in Combination with Other Treatments in Subjects with Multiple Myeloma

    Scottsdale/Phoenix, AZ

  10. Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL

    Rochester, MN

.

Mayo Clinic Footer